# Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome

> **NCT03319420** · PHASE4 · COMPLETED · sponsor: **Ocuwize LTD** · enrollment: 60 (actual)

## Conditions studied

- Dry Eye Due to Sjögren's Syndrome

## Interventions

- **DRUG:** LO2A eye drops
- **DRUG:** Systane Ultra UD

## Key facts

- **NCT ID:** NCT03319420
- **Lead sponsor:** Ocuwize LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-29
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03319420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03319420, "Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03319420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*